Abstract
Pharmacologic treatment of restenosis following coronary angioplasty has completely failed. The most widely accepted cause is formation of neointimal hyperplasia, considered a result of uncontrolled medial smooth muscle cell proliferation [1–5]. Studies in the rat carotid artery injury model has been the basis of this paradigm, having been documented in many studies [6, 7]. Therapies aimed at inhibiting proliferation have been quite successful in rat arterial injury [8, 9]. Yet when applied to large scale patient trials, these therapies have failed to exhibit any effect whatsoever on the loss of minimal lumen diameter (MLD) [10]. Reasons for these failures are unclear, but may relate in part to an incomplete understanding of cell kinetics in the growth of human neointimal hyperplasia. The literature is conflicting regarding the role of proliferation in human restenosis. Two studies of human restenotic lesions obtained using directional atherectomy demonstrated opposite conclusions. Pickering and colleagues [11] found peak cellular proliferation rates of about 20%, while in a similar study, O’Brien [12] reported a proliferation rate of less than 1%. Much debate has surfaced about the reasons for these divergent results, but centers on questions of technical factors such as tissue fixation methods and visual interpretation of positive cells by proliferating cell nuclear antigen (PCNA) staining.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Austin G, Ratliff N, Hollman J, Tabei S, Phillips D: Intimai proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6:369–375.
Bohon WE, Mikulka WR, Healy CG, Schmhtling RJ, Kenyon NS: Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry 1992; 13(2): 117–126.
Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR: Original Contributions: Time Course of Smooth Muscle Cell Proliferation in the Intima and Media of Arteries Following Experimental Angioplasty. Circulation Research 1990; 67(3):651–659.
Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SBB: Coronary intimai proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992; 20(2):467–474.
Karsch KR, Haase KK, Wehrmann M, Hassenstein S, Hanke H: Smooth muscle cell proliferation and restenosis after stand alone coronary excimer laser angioplasty. J Am Coll Cardiol 1991; 17(4):991–994.
Clowes A, Reidy M, Clowes M: Kinetics of cellular proliferation after arterial injury: I. Smooth muscle growth in absence of endothelium. Lab Invest 1983; 49:327–332.
Clowes A, Clowes M, Fingerle J, Reidy M: Kinetics of cellular proliferation after arterial injury V. Role of acute distension in the induction of smooth muscle proliferation. Lab Invest 1989; 49:360–364.
Powell J, Clozel J, Muller R et al.: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245:186–188.
Powell J, Muller R, Baumgartner H: Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J Am Coll Card 1991; 17(6):137B–142B.
Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?: Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86(1): 100–110.
Pickering J, Weir L, Jakanowski J, Kearney M, Isner J: Proliferative Activity in Peripheral and Coronary Atherosclerotic Plaque among Patients Undergoing Percutaneous Revascularization. J Clin Invest 1993; 91:1469–1480.
O’Brien E, Alpers C, Stewart D et al.: Proliferation in Primary and Restenotic Coronary Atherectomy Tissue. Implications or Antiproliferative Therapy. Circ Res 1993; 73(223-231).
Schwartz RS, Edwards WD, Huber KC et al.: Coronary restenosis: prospects for solution and new perspectives from a porcine model. Mayo Clin Proc 1993; 68(1):54–62.
Edstrom SS, Gustafsson B, Stenman O, Lyden E, Stein H, Westin T: Proliferative pattern of head and neck cancer. Am J Surg 1991; 162(4):412–416.
Franchi F, Rossi FF, Seminara P, Cascino A, Barone C, Scucchi L: Cell kinetics of gastrointestinal tumors after different nutritional regimens. A preliminary report. J Clin Gastroenterol 1991; 13(3):313–315.
Giordano M, Danova M, Pellicciari C et al.: Proliferating cell nuclear antigen (PCNA) /cyclin expression during the cell cycle in normal and leukemic cells. Leuk Res 1991; 15(11):965–974.
Henry MJ, Stanley MW, Swenson B, Connolly JE, Bates H: Cytologic assessment of tumor cell kinetics: applications of monoclonal antibody Ki-67 to fine-needle aspiration smears. Diagn Cytopathol 1991; 7(6):591–596.
Horny HP, Horst HA: Proliferation of invasive breast carcinomas and colorectal adenocarcinomas: an immunohistochemical in situ investigation with the monoclonal antibody Ki-67. Zentralbl Allg Pathol 1988; 134(6):547–554.
Kamel OW, Le Brun DP, Davis RE, Berry GJ, Warnke RA. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Correlation with Ki-67 labeling. Am J Pathol 1991;138(6):1471–1477.
Nobuyoshi M, Kimura T, Nosaka H et al.: Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12:616–623.
Shackney S, Ritch P: Cell Kinetics. In: Chabner B, ed. Pharmacologie Principles of Cancer Treatment. Philadelphia: W.B. Saunders, 1982.
Lipponen PK, Eskelinen MJ: Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description. Anticancer Res 1992; 12(2):577–583.
Rosa JC, Mendes R, Filipe MI, Morris RW: Measurement of cell proliferation in gastric carcinoma: comparative analysis of Ki-67 and proliferative cell nuclear antigen (PCNA). Histochem J 1992; 24(2):93–101.
Iversen OH: The cell kinetics of the inflammatory reaction. Introduction and overview. Curr Top Pathol 1889; 79:1–5.
Arey L: Wound Healing. Physiol Rev 1936; 16:327–333.
Simons M, Edelman ER, De Keyser J, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 1992; 356:62–65.
Simons M, Rosenberg R.: Antisense approach to smooth muscle proliferation. Circulation 1991; 84(4):II–342.
Shi Y, Fard A, Galeo A et al.: Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90(2):944–951.
Morishita R, Gibbons GH, Ellison KE et al.: Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy. Transactions of the Association of American Physicians 1993; 106:54–61.
Speir E, Epstein SE: Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation 1992; 86(2):538–547.
Ohno T, Gordon D, San H et al.: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265(5173):781–784.
Clowes A, Schwartz S: Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985; 56:139–145.
Jawien A, Bowen PDF, Lindner V, Schwartz SM, Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimai thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89(2):507–511.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schwartz, R.S. et al. (1997). Vascular Cell Proliferation Dynamics: Implications for Gene Transfer and Restenosis. In: March, K.L. (eds) Gene Transfer in the Cardiovascular System. Developments in Cardiovascular Medicine, vol 189. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6277-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6277-1_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7881-5
Online ISBN: 978-1-4615-6277-1
eBook Packages: Springer Book Archive